Overview

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Status:
Not yet recruiting
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior to placebo in reducing NT-proBNP at Week 16.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme LLC